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Abstract By PCR and EST database searches we have
identified three novel BNIP1 splice variants, and found that
one of them, BNIP1-b, contains a highly conserved BH3 domain.
The BNIP1 gene has been assigned to chromosome 5q33^34.
Using in vitro protein-protein interaction assays, all BNIP1
variants were shown to interact with BCL2 and also with
BCL2L1 (previously Bcl-xL). These interactions are BH3-
independent. Furthermore, the BNIP1 variants cannot interact
with BAX. The results suggest that the BNIP1 variants are novel
members of the BCL2 family but function through a mechanism
different from other BH3-only members.
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1. Introduction
Programmed cell death or apoptosis plays an important
role in the development of multicellular organisms [1] and in
pathological processes [2]. Apoptosis is under tight control of
rather complex regulatory circuits which are evolutionarily
conserved from the nematode Caenorhabditis elegans to
man. Proteins of the BCL2 family turned out to be important
regulators of apoptosis [3].
The BCL2 family consists of a growing number of proteins,
some of them protect cells from apoptosis, such as BCL2,
BCL2L1, BCL2A1, and MCL1, but others promote apopto-
sis, such as BAX, BAK, and BAD. Several domains in the
BCL2 family proteins are evolutionarily conserved, which are
described as BCL2 homology (BH) domains. BH1 and BH2
domains are common throughout the family [4]. Anti-apop-
totic members share BH3 and BH4 domains [5,6], whereas
pro-apoptotic members of the family, such as BAX and
BAK, share the BH3 domain, which, however, has di¡erent
features from that of the anti-apoptotic members [5^8]. With-
in the family, protectors and promoters of cell death interact
with each other by forming homodimers or heterodimers.
BCL2 interacts with members of the BCL2 family, but it
can also associate with other proteins as shown by yeast two-
hybrid methods, by protein interaction cloning techniques or
immunoprecipitation from human cell extracts [9^14]. How-
ever, the precise function in apoptosis has not been deter-
mined yet for the majority of these proteins.
In the present study, we report the isolation of three novel
BNIP1 variants, one of them contains a highly conserved BH3
domain. All BNIP1 variants are able to interact with BCL2,
BCL2L1 but not with BAX.
2. Materials and methods
2.1. Cloning of human BNIP1 variants and chromosomal location of
BNIP1
PCR was performed to clone BNIP1 and BNIP1-a from a human
prostate V-gt11 cDNA library (Clontech). The 5P primer was designed
according to the previously published BNIP1 cDNA sequence [10]
and contains an EcoRI site (underlined) £anking the initiation codon
(bold) (5P-GGAATTCCATATGGCGGCTCCCCAAGAC-3P). The 3P
reverse primer is complementary to sequences downstream of the
BNIP1 stop codon (bold) (5P-GGAATTCGTCGACACTGTGTTC-
CATCCAACCTG-3P). The PCR products were cloned in the EcoRI
site of vector pZero 1-1 (Invitrogen) and sequenced. Searching the
GenBank database of human expressed sequence tags (ESTs) with
the BNIP1 cDNA sequence, a 351 nt EST sequence (GenBank acces-
sion number H11663) was found and sequenced, its gene was named
BNIP1-b. A 495 bp EST (GenBank accession number W95979) was
also identi¢ed and termed BNIP1-c. The search of the GenBank data-
base for STSs using BNIP1-b as a template revealed that a human
STS WI-6822 (accession number G06277) matches 100% to the nu-
cleotides +941 to +1229 of the BNIP1-b sequence. BNIP1 was located
on chromosome 5 using the NCBI Unigen program. EMBL/Gen-
Bank/DDBJ accession numbers for BNIP1-a, BNIP1-b and BNIP1-c
are AF083956, AF083957 and AF083958, respectively.
2.2. Plasmid constructs and in vitro transcription/translation
cDNA of bacterial chloramphenicol acetyltransferase (CAT), hu-
man BCL2L1, human BCL2, human BAX, and the BNIP1 variants
were sub-cloned into pcDNA3 (Invitrogen) using standard cloning
procedures. All constructs were con¢rmed by sequencing. For coupled
in vitro transcription/translation, 2 Wg of plasmids were linearized
(creating 5P overhangs) and used with TNT wheat germ lysates (Prom-
ega, Inc.) in the presence of [35S]methionine according to the suppli-
er’s manual.
2.3. In vitro interaction assay
6His-BCL2, 6His-BCL2L1, 6His-BAX, and GST-BCL2 fusion pro-
teins were puri¢ed from bacterial extracts (provided by Dr. G. Fen-
drich, Novartis). Fusion proteins (10 Wg) were prebound to Ni2-TNA
chelation resins (Qiagen) or glutathione-Sepharose beads (Qiagen),
mixed with 10 Wl of in vitro translated, 35S-labeled proteins for 1 h
at 4‡C on a rotator, and then washed 5 times in NETN bu¡er (20 mM
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% Nonidet P-40).
The resin or beads were resuspended in Laemmli bu¡er, heated to
100‡C for 5 min, vortexed, and the resulting supernatants were ap-
plied to 12% SDS-PAGE. Gels were dried and exposed to an X-ray
¢lm or phosphate image screen (Molecular Dynamics).
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2.4. Northern blot analysis
The mRNA expression pattern of the BNIP1 variants was deter-
mined by Northern blots on a multiple tissue membrane from Clon-
tech. Probes were prepared from PCR products using primer set a
(5P-CCAGTTCTCTATCAAAGGGC-3P and 5P-ACTGAAGGTAA-
CAGGT-3P), which ampli¢es an 129 nt DNA fragment encoding do-
main B, and primer set b (5P-AGCAATCAGGCCTCATG-3P and
5P-TTGCCTTAAGAGATC-3P), which ampli¢es a 102 nt DNA frag-
ment encoding domain D of BNIP1vs.
3. Results
3.1. BNIP1 and its variants
BNIP1 has been suggested as a target for BCL2 interaction
[10]. During the course of cloning BNIP1, we further identi-
¢ed three novel, alternatively spliced forms of BNIP1 by use
of PCR and by search of the EST database (Fig. 1A). Brie£y,
PCR was performed on phage DNA of a prostate cDNA
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Fig. 1. Isolation of cDNAs encoding three novel isoforms of BNIP1: BNIP1-a, BNIP1-b and BNIP1-c. A: Schematic representation of the
BNIP1 variants. Domains A^F were de¢ned in relation to the deduced amino acid sequence of BNIP1-b. The black box represents the putative
transmembrane domain (domain F). Dotted lines indicate putative splice regions. B: Relationship of the four BNIP1 variants showing the pre-
dicted amino acid sequence of BNIP1vs. The BH3 domain is underlined. ‘ANK1’, ‘ANK2’ and ‘TM’ represent ankyrin repeat-like motifs and
the putative transmembrane domain, respectively. C: Alignment of the putative BH3 domain of BNIP1 with the BH3 domain of other mem-
bers of the BCL2 family. Asterisks indicate conserved amino acids. D: Distribution of BNIP1b and BNIP1c in human tissues. A 129 nt DNA
probe labeled with digoxigenin was hybridized to poly(A) RNA from the following human tissues: pancreas (1), kidney (2), skeletal muscle
(3), liver (4), lung (5), placenta (6), brain (7) and heart (8). The same membrane was reprobed with L-actin for calibration (not shown). E:
Schematic illustration of the chromosomal localization of the BNIP1 gene. The search of the GenBank database for STSs was done with nu-
cleotides +941 to +1229 of the BNIP1-b sequence. The NCBI Unigen program was used for chromosomal localization of BNIP1.
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library to amplify the entire coding region of BNIP1 [10]. Two
bands were observed as PCR products, each band was cloned
and subjected to sequence analysis (not shown). The sequence
of these PCR products demonstrated that the longer one cor-
responds to BNIP1 cDNA and the shorter one is a splicing
variant of BNIP1 which contains a 102 nt in-frame deletion
and was named BNIP1-a. Subsequently, a Blast Search of the
GenBank database ESTs was performed using the cDNA se-
quence of BNIP1 and we identi¢ed two other forms of
BNIP1, termed BNIP1-b and BNIP1-c. BNIP1-b was found
in an infant brain cDNA library and contains a 129 nt in-
frame insertion. BNIP1-c was isolated from a fetal heart
cDNA library and has the same 129 nt in-frame insertion
but also the same 102 nt in-frame deletion as in BNIP1-a.
Based on the splicing events, we de¢ne six regions, A^F, for
the deduced amino acid sequence of BNIP1-b (Fig. 1A). We
refer to BNIP1 and its variants as BNIP1vs. The predicted
amino acid sequence of BNIP1vs showed no signi¢cant ho-
mology to known proteins. However, alignment of the C-ter-
minus of BNIP1vs (Fig. 1B) with proteins in the database
revealed an interesting region with similarities to the ankyrin
repeats of Notch 2 [15] and ICP4 [16], which is a repeated
sequence motif present in a variety of proteins whose common
function involves binding to other proteins [17]. Most inter-
estingly, region D, which is present in BNIP1 and BNIP1-b,
contains a fully conserved BH3 domain of 16 amino acids
(Fig. 1C). Therefore, the BNIP1vs could be novel members
of the BCL2 family.
Northern blot hybridization of the RNA from various hu-
man tissues revealed hybridizing bands of about 1.35 kb (Fig.
1D). Messages were detected in placenta, lung, liver, skeletal
muscle, kidney, pancreas, testis and small intestine with a
probe prepared from the 129 nt DNA sequence encoding do-
main B, which is present in BNIP1-b and BNIP1-c. Low or no
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Table 1
Di¡erential expression of BNIP1 variants
Probe Heart Brain Placenta Lung Liver Skeletal muscle Kidney Pancreas
a +/3 +/3 + + + + + +/3
b ++ ++ + + ++ ++ + ++
Spleen Thymus Prostate Testis Ovary Small intestine Colon Peripheral blood leukocytes
a +/3 3 +/3 ++ 3 ++ 3 3
The mRNA expression pattern of BNIP1 variants was determined by Northern blots on a multiple tissue membrane from Clontech. Probes were
prepared from PCR products using primer set a which ampli¢es a 129 nt DNA fragment encoding domain B and primer set b which ampli¢es a 102
nt DNA fragment encoding domain D of BNIP1vs (see Section 2). +/3 stands for low gene expression, ++ for high expression and 3 for no
expression.
Fig. 2. Analysis of interaction of BNIP1vs with BCL2 family proteins by in vitro binding assays. A: Protein expression by the TNT translation
system (Promega) in the presence of [35S]methionine. Results from two independent experiments are presented in the right and left panels.
(TM3) represents proteins lacking the C-terminal transmembrane domain. ‘a’, ‘b’ and ‘c’ denote BNIP1-a, BNIP1-b and BNIP1-c, respectively.
Fusion proteins for 6His-BCL2 (B and C), 6His-BCL2L1 (D) and 6His-BAX (E) were puri¢ed from bacterial expressions. Fusion proteins were
prebound to Ni2-TNA chelation resins, mixed with in vitro translated, 35S-labeled BNIP1vs proteins. After extensive washes, the resin was re-
suspended in Laemmli bu¡er for SDS-PAGE. Gels were dried and exposed to a phosphor image screen (Molecular Dynamics).
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expression was seen in other tissues (Table 1). With the 102 nt
probe present in BNIP1 and BNIP1-b (encoding domain D),
messages were detected in heart, brain, liver, skeletal muscle
and pancreas (Table 1). At this stage it is not possible to ¢nd
proper probes to further distinguish the expression patterns of
individual BNIP1 variants yet.
A computer search with the BNIP1-b cDNA sequence of a
STS database revealed a human STS WI-6822 (GenBank ac-
cession number G06277) matching nucleotides +941 to +1229
of the BNIP1-b sequence. The genomic locus of BNIP1 could
be mapped to human chromosome 5 between the markers
D5S504 and D5S425, thus localizing the BNIP1 gene to chro-
mosome 5 at 5q33^34 (175^179 cM) (Fig. 1E).
3.2. Interaction of BNIP1vs with BCL2 family proteins
Boyd et al. [10] have previously demonstrated that the
BNIP1 protein can interact with E1B 19K protein and
BCL2 in a yeast two-hybrid assay. The interaction was con-
¢rmed by immunoprecipitation. It is therefore interesting to
examine whether the BNIP1vs are capable of interacting with
BCL2 family members. Further comparison of the binding of
di¡erent BNIP1 variants may allow us to de¢ne the structural
regions which are required for interaction with BCL2. We
initially determined their interaction with BCL2 in an in vitro
protein-protein interaction assay. BCL2 was expressed as a
6His fusion protein in Escherichia coli and immobilized on a
Ni2-TNA chelation resin before incubation with 35S-labeled
BNIP1vs that had been prepared by in vitro transcription/
translation (Fig. 2A) using wheat germ extracts. After exten-
sive washing, proteins which interacted physically with BCL2
were collected and detected after SDS-PAGE. In vitro trans-
lated 35S-labeled BAX and CAT proteins served as positive
and negative controls (Fig. 2B,C). As shown in Fig. 2B,
BNIP1, BNIP1-a, BNIP1-b and BNIP1-c could interact with
6His-BCL2. BAX interacted with BCL2 but the CAT protein
did not (Fig. 2C).
As seen in Fig. 1, BNIP1-a has a 34 amino acid (domain D)
in-frame deletion with respect to BNIP1 and BNIP1-b has a
43 amino acid (domain B) in-frame insertion. The comparison
of the interactions of BNIP1, BNIP1-a and BNIP1-b with
BCL2 (Fig. 2B) does not show major di¡erences. This sug-
gests that the interaction of BNIP1vs with BCL2 is not de-
pendent on domains B and D. The membrane domain (F) is
also not essential for the interaction of BNIP1vs with BCL2
(Fig. 2C).
Since all members of the BCL2 family share some homol-
ogy in conserved BH1, BH2 or BH3 domains [18,19], we
examined whether BNIP1vs could interact with BCL2L1
and BAX. As described above, BCL2L1 and BAX were ex-
pressed as 6His fusion proteins. Fig. 2D shows that BNIP1vs
could interact with BCL2L1, but they were not able to bind to
BAX (Fig. 2E). The speci¢city of the interactions was veri¢ed
by the use of CAT protein which failed to bind to BCL2L1
and BAX (data not shown).
4. Discussion
The experimental data characterize BNIP1 and its variants
as proteins interacting with BCL2 and BCL2L1. We show
that the BNIP1 gene encodes four alternatively spliced pro-
teins, called BNIP1, BNIP1-a, BNIP1-b and BNIP1-c (Fig. 1).
They are expressed di¡erentially in various tissues (Table 1).
Interestingly, all BNIP1vs can interact with BCL2 (Fig. 2B,C)
and BCL2L1 (Fig. 2D), but not with BAX (Fig. 2E), implying
that the binding sites for BNIP1vs are conserved in BCL2 and
BCL2L1 but are absent in BAX.
An interesting ¢nding is that BNIP1-b and BNIP1 contain
a conserved BH3 domain. It is located in section D of the
sequence which is missing in BNIP1-a and BNIP1-c. A closer
sequence comparison of BNIP1-b and BNIP1 with members
of the BCL2 family indicates that the BNIP1vs do not share
BH1 and BH2 domains. The BH3 domain has been demon-
strated, in many studies, as a stretch of amino acids that is
required for interaction between pro-apoptotic and anti-apop-
totic members, and to promote cell death (for review see
[20,21]). Therefore, BNIP1-b and BNIP1 may be novel
BH3-only members of the BCL2 family.
What could be the function of the BNIP1 variants in vivo?
Since BNIP1-b and BNIP1 contain a BH3 domain but
BNIP1-a and BNIP1-c do not, they may have opposite func-
tions in apoptosis similar to that observed in Bcl-xL vs. Bcl-xS
[22] and CED-4L vs. CED-4S [23]. However, our preliminary
data on overexpression of BNIP1vs in both rat REF52 and
mouse FL5.12 cells show that they do not function as direct
promoters or inhibitors of apoptosis (data not shown). More-
over, the interaction of BNIP1vs with BCL2 and BCL2L1 is
independent of the BH3 domain (Fig. 2), suggesting that
BNIP1vs may function through a mechanism di¡erent from
other BH3-only members. One possibility is that the BH3
domain in BNIP1vs is hidden, therefore the exposure of the
BH3 domain is required for their function. Additional experi-
ments are necessary to verify these possibilities and to explore
the function of BNIP1vs.
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